Sumo Group higher-than-expected results reflect strong performance

Sumo Group plc (LON:SUMO), the award-winning provider of creative and development services to the video games and entertainment industries, has announced that its revenue and Adjusted EBITDA for the full year ended 31 December 2020 are expected to be ahead of consensus market expectations* with Adjusted EBITDA for the year of at least £16.0m. The higher-than-expected results reflect strong performances from Sumo Digital and our latest acquisition, Pipeworks, and higher than expected royalty income, during the year.

Net cash at 31 December 2020 was ahead of management expectations at £6.8m due to a number of timing effects, which are expected to reverse during 2021. Headcount increased to 1,043 at the year-end, including 139 people at Pipeworks and 40 at Lab42, an increase of 277 on the prior year (31 December 2019: 766).

The Group expects to announce its FY 20 results on Wednesday, 31 March 2021.

* Consensus market expectation for Adjusted EBITDA in FY 20 is currently £14.8m. Adjusted EBITDA is as defined in the Group’s unaudited half year results 2020, announced on 30 September 2020, and is stated after deducting operating lease costs capitalised under IFRS 16.

Carl Cavers, Chief Executive Officer of Sumo Group, said:

“The year has been extraordinary in many respects. Sumo Group performed very strongly in an already fast-growing market that was further boosted by the effects of the pandemic. We are a people business and I’d particularly like to thank all of our people for making our collective response to the pandemic a truly inspirational story which unfortunately isn’t over yet. We’re keen to return to some level of normality in our studios in the various countries as the vaccine roll-out progresses. In the meantime, we continue to work well from home and have the ongoing support from our partners to do so. We are focused on making great games and continue to operate at good levels of efficiency with no significant delays to production schedules.

We announced or launched a relatively large number of Client-IP and Own-IP games in 2020, including Spyder, Little Orpheus, Sackboy A Big Adventure and Hood. We also completed two great acquisitions, Lab42 and Pipeworks. I was delighted to welcome both of these teams to Sumo Group and am pleased to report that both businesses are fitting in very well and have performed ahead of our expectations. Pipeworks and Genvid announced Rival Peak, a massive interactive live event styled game for Facebook livestream in December.

Our royalty performance in FY 20 is also ahead of our expectations. We recognised royalties on eight games, including two Own-IP.

While our teams across our 12 studios in four countries are nearly all working remotely, in accordance with the relevant local regulations, we continue to manage our studio estate. Both our studios in the North East of England and The Chinese Room in Brighton have moved to new larger premises to accommodate our expected growth.

We are also pursuing a number of acquisition opportunities and new studio locations, as well as working hard to recruit more talented people to join our teams globally. 

The Board looks forward to announcing the Final Results in March and providing shareholders with a full update on the Group’s progress. We are proud of our achievements in what has been a challenging year and remain very positive about our prospects for 2021 and beyond.”

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Sumo Group Plc

    More articles like this

    Guild Esports sign two-year gaming chair sponsorship with Razer

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global teams organisation and lifestyle brand, has welcome Razer as the Company’s Official Gaming Chair Partner with the signing of a two-year global sponsorship deal. The total contract value, which

    Redde Northgate trading ahead of expectations

    Redde Northgate plc (LON:REDD), the leading integrated mobility solutions platform providing services across the vehicle lifecycle, has announced a trading update for the year ended 30 April 2022, ahead of its results for the year scheduled

    Inchcape

    Inchcape update on Russian operations

    Inchcape plc (LON:INCH) is deeply saddened by the ongoing conflict in Ukraine and the enormous humanitarian impact on all those affected. We share the hopes of the world for a peaceful resolution. In light of the current

    STRIX GROUP PLC ORD 1P

    Strix Group to conduct investor presentation on 31st March 2022

    Strix Group plc (LON:KETL), the global leader in the design, manufacture and supply of kettle safety controls and other complementary water temperature management components will be conducting an investor presentation covering their Full Year results to the period

    City of London Investment Group plc

    City of London Investment Group Barry Olliff increases holding

    City of London Investment Group plc (LON:CLIG), a leading specialist asset management group offering a range of institutional and retail products investing primarily in closed-end funds, stated that it has been notified that Stable View III LP,

    CentralNic

    CentralNic Group continue to beat expectations (Analyst Interview)

    CentralNic Group Plc (LON:CNIC) is the topic of conversation when Bob Liao Director and Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Bob provides us with an overview of VGL, explains how the acquisition fits in with CentalNic’s business,

    Guild Esports wins fifth major trophy

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global team organisation and lifestyle brand, has announced that it has won its fifth major trophy after its Fortnite pro-player, Henrik Mclean (‘Hen’), achieved first place in the prestigious Fortnite

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous